vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2023-2-129-139vtio-1643Research ArticleТрансплантомикаTransplantomicsГалектин-3 у реципиентов солидных органов: роль в развитии патологии трансплантата и перспективы примененияGalectin-3 in solid organ recipients: role in graft pathology and prospects for useВеликийД. А.VelikiyD. A.

Дмитрий Алексеевич Великий - ученый секретарь ФГБУ "НМИЦ ТИО им.ак.В.И.Шумакова" Минздрава России, доктор медиинских наук.

Москва

Moscow

dim_vel@mail.ruОсобливаяМ. А.OsoblivayaM. A.

Особливая Мария Александровна - врач-клинической лабораторной диагностики.123182, Москва, ул. Щукинская, д. 1. Тел. (499) 193-87-62

Moscow

Osoblivaya-091@yandex.ruШевченкоО. П.ShevchenkoO. P.

Ольга Павловна Шевченко - руководитель отдела, доктор медиинских наук, заслуженный деятель науки РФ.

Москва

Moscow

transplant2009@mail.ruФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian FederationФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский университет)РоссияShumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov UniversityRussian Federation202315072023252129139Copyright © Великий Д.А., Особливая М.А., Шевченко О.П., 20232023Великий Д.А., Особливая М.А., Шевченко О.П.Velikiy D.A., Osoblivaya M.A., Shevchenko O.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1643

Галектин-3 – важный регулятор процессов клеточной адгезии, миграции, пролиферации, дифференцировки и апоптоза при физиологических и патологических состояниях. Особое значение галектин-3 имеет при развитии заболеваний, связанных с хроническим воспалением и фиброзом. Последние годы показано изменение концентрации галектина-3 в крови реципиентов солидных органов при верификации патологии трансплантата почки, печени, сердца и легких. Результаты исследований содержания и динамики галектина-3 у реципиентов солидных органов могут служить для оценки состояния трансплантата с помощью новых малоинвазивных методов и выявления терапевтических мишеней для персонифицированной терапии. Появляются первые данные клинических исследований о фармакологическом ингибировании галектина-3. В настоящем обзоре суммированы современные представления о роли галектина-3 в развитии патологии трансплантата и перспективах его применения в качестве диагностического маркера и терапевтической мишени у реципиентов солидных органов.

Galectin-3 (Gal-3) is an important regulator of cell adhesion, migration, proliferation, differentiation and apoptosis under pathophysiological conditions. It plays a crucial role in diseases associated with chronic inflammation and fibrosis. In recent years, there have been reports indicating changes in serum Gal-3 levels in solid organ transplant recipients in the verification of kidney, liver, heart and lung transplant pathologies. Studies on Gal-3 levels and dynamics in solid organ recipients may serve to assess graft conditions using new minimally invasive methods and to identify therapeutic targets for personalized therapy. The first clinical trial data on Gal-3 pharmacological inhibition are emerging. This review summarizes the current understanding of the role of Gal-3 in transplant pathology and the prospects for its use as a diagnostic marker and therapeutic target in solid organ recipients.

галектин­3трансплантация солидных органовпатология трансплантатаgalectin­3solid organ transplantationgraft pathologyReferencesШевченко АO. Методы оценки и сравнительного анализа клинической эффективности биомаркеров при диагностике острого коронарного синдрома. Биомаркеры в лабораторной диагностике. Под ред. В.В. Долгова, О.П. Шевченко, А.О. Шевченко. М.: Триада, 2014. 288 с.Shevchenko AO. Metody ocenki i sravnitel’nogo analiza klinicheskoj jeffektivnosti biomarkerov pri diagnostike ostrogo koronarnogo sindroma. Biomarkery v laboratornoj diagnostike. Pod red. V.V. Dolgova, O.P. Shevchenko, A.O. Shevchenko. M.: Triada, 2014. 288 s.Шевченко ОП, Аксенова АВ, Улыбышева АА, Можейко НП, Никитина ЕА, Орлов ВИ и др. Сравнительный анализ диагностической значимости панелей биомаркеров у реципиентов сердца в отдаленные сроки после трансплантации. Вестник трансплантологии и искусственных органов. 2017. 19 (2): 27–33.Shevchenko OP, Aksyonova AV, Ulybysheva АА, Mozheiko NP, Nikitina EA, Orlov VI et al. Comparative analysis of diagnostic significance of biomarkers’ panels in cardiac recipients in the long term period after transplantation. Russian Journal of Transplantology and Artificial Organs. 2017; 19 (2): 27–33.Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019 Jul; 209: 121–137. doi: 10.1016/j.trsl.2019.03.001.Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019 Jul; 209: 121–137. doi: 10.1016/j.trsl.2019.03.001.Лахтин М, Лахтин В, Алешкин В, Афанасьев С. Лектины полезных микробов: системная организация, функционирование и функциональное суперсемейство. Польза. Микробы. 2011; 2: 155–165.Lahtin M, Lahtin V, Aleshkin V, Afanas’ev S. Lektiny poleznyh mikrobov: sistemnaja organizacija, funkcionirovanie i funkcional’noe supersemejstvo. Pol’za. Mikroby. 2011; 2: 155–165.Slack RJ, Mills R, Mackinnon AC. The Therapeutic Potential of Galectin-3 Inhibition in Fibrotic Disease. Int J Biochem Cell Biol. 2021; 130: 105881.Slack RJ, Mills R, Mackinnon AC. The Therapeutic Potential of Galectin-3 Inhibition in Fibrotic Disease. Int J Biochem Cell Biol. 2021; 130: 105881.Argüeso P, Panjwani N. Focus on molecules: Galectin-3. Exp Eye Res. 2011 Jan; 92: 2–3.Argüeso P, Panjwani N. Focus on molecules: Galectin-3. Exp Eye Res. 2011 Jan; 92: 2–3.Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and nonautoimmune nephropathies. Autoimmun Rev. 2017; 16: 34–47.Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and nonautoimmune nephropathies. Autoimmun Rev. 2017; 16: 34–47.Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem. 1999; 264: 569–576.Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem. 1999; 264: 569–576.Newlaczyl AU, Yu LG. Galectin-3 – a jack-of-all-trades in cancer. Cancer Lett. 2011; 313: 123–128.Newlaczyl AU, Yu LG. Galectin-3 – a jack-of-all-trades in cancer. Cancer Lett. 2011; 313: 123–128.De Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015; 240 (8): 1019–1028.De Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015; 240 (8): 1019–1028.Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014; 52 (10): 1413–1423.Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014; 52 (10): 1413–1423.Dumic J, Dabelic S, Flögel M. Galectin-3: An open-ended story. Biochim Biophys Acta. 2006; 1760: 616–635.Dumic J, Dabelic S, Flögel M. Galectin-3: An open-ended story. Biochim Biophys Acta. 2006; 1760: 616–635.Ochieng J, Leite­Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998 May 29; 246 (3): 788–791. doi: 10.1006/bbrc.1998.8708.Ochieng J, Leite­Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998 May 29; 246 (3): 788–791. doi: 10.1006/bbrc.1998.8708.Karlsson A, Christenson K, Matlak M, Björstad A, Brown KL, Telemo E et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009 Jan; 19 (1): 16–20. doi: 10.1093/glycob/cwn104.Karlsson A, Christenson K, Matlak M, Björstad A, Brown KL, Telemo E et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009 Jan; 19 (1): 16–20. doi: 10.1093/glycob/cwn104.Chen SC, Kuo PL. The role of Galectin-3 in the kidneys. Int J Mol Sci. 2016; 17 (4): 565.Chen SC, Kuo PL. The role of Galectin-3 in the kidneys. Int J Mol Sci. 2016; 17 (4): 565.Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages. Biochim Biophys Acta. 2012 Sep; 1820 (9): 1383–1390.Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages. Biochim Biophys Acta. 2012 Sep; 1820 (9): 1383–1390.Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galectin-3 Is a Potential Mediator for Atherosclerosis. J Immunol Res. 2020 Feb 14; 2020: 5284728.Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galectin-3 Is a Potential Mediator for Atherosclerosis. J Immunol Res. 2020 Feb 14; 2020: 5284728.Montes M, Sanford BL, Comiskey DF, Chandler DS. RNA Splicing and Disease: Animal Models to Therapies. Trends Genet. 2019 Jan; 35 (1): 68–87.Montes M, Sanford BL, Comiskey DF, Chandler DS. RNA Splicing and Disease: Animal Models to Therapies. Trends Genet. 2019 Jan; 35 (1): 68–87.Gajendra Singh, Divisha Rao, Alok Kumar. Chapter 1 – Molecular Basis of Neurological Disorders. The Molecular Immunology of Neurological Diseases. Academic Press, 2021: 1–13.Gajendra Singh, Divisha Rao, Alok Kumar. Chapter 1 – Molecular Basis of Neurological Disorders. The Molecular Immunology of Neurological Diseases. Academic Press, 2021: 1–13.Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta. 2002; 1572 (2–3): 274–284.Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta. 2002; 1572 (2–3): 274–284.Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxylterminal lectin domain in self-association of galectin-3. Biochemistry. 1998 Mar 24; 37 (12): 4086–4092. doi: 10.1021/bi971409c.Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxylterminal lectin domain in self-association of galectin-3. Biochemistry. 1998 Mar 24; 37 (12): 4086–4092. doi: 10.1021/bi971409c.Chen WJ, Yin K, Zhao GJ, Fu YC, Tang CK. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis. 2012 Jun; 222 (2): 314–323. doi: 10.1016/j.atherosclerosis.2012.01.020.Chen WJ, Yin K, Zhao GJ, Fu YC, Tang CK. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis. 2012 Jun; 222 (2): 314–323. doi: 10.1016/j.atherosclerosis.2012.01.020.Song Z, Zhong X, Ning Z, Song X. The Protective Effect of miR-27-3p on Ischemia-Reperfusion-Induced Myocardial Injury Depends on HIF-1α and Galectin-3. J Cardiovasc Transl Res. 2022 Aug; 15 (4): 772–785.Song Z, Zhong X, Ning Z, Song X. The Protective Effect of miR-27-3p on Ischemia-Reperfusion-Induced Myocardial Injury Depends on HIF-1α and Galectin-3. J Cardiovasc Transl Res. 2022 Aug; 15 (4): 772–785.Zhang M, Cheng K, Chen H, Tu J, Shen Y, Pang L, Wu W. MicroRNA-27 attenuates pressure overload-Induced cardiac hypertrophy and dysfunction by targeting galectin-3. Arch Biochem Biophys. 2020 Aug 15; 689: 108405. doi: 10.1016/j.abb.2020.108405.Zhang M, Cheng K, Chen H, Tu J, Shen Y, Pang L, Wu W. MicroRNA-27 attenuates pressure overload-Induced cardiac hypertrophy and dysfunction by targeting galectin-3. Arch Biochem Biophys. 2020 Aug 15; 689: 108405. doi: 10.1016/j.abb.2020.108405.El­Kott AF, Shati AA, Ali Al­Kahtani M, Alharbi SA. The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription. J Food Biochem. 2019 Oct 11; 43 (12).El­Kott AF, Shati AA, Ali Al­Kahtani M, Alharbi SA. The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription. J Food Biochem. 2019 Oct 11; 43 (12).Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genisteininduced G(2)/M arrest and inhibits apoptosis. Carcinogenesis. 2000 Nov; 21 (11): 1941–1945. doi: 10.1093/carcin/21.11.1941.Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genisteininduced G(2)/M arrest and inhibits apoptosis. Carcinogenesis. 2000 Nov; 21 (11): 1941–1945. doi: 10.1093/carcin/21.11.1941.Dickstein K, Cohen­Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole­Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct; 10 (10): 933–989. doi: 10.1016/j.ejheart.2008.08.005.Dickstein K, Cohen­Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole­Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct; 10 (10): 933–989. doi: 10.1016/j.ejheart.2008.08.005.Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med. 2018 Feb; 41 (2): 599–614.Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med. 2018 Feb; 41 (2): 599–614.Драпкина О.М., Деева Т.А. Галектин-3 – биомаркер фиброза у пациентов с метаболическим синдромом. Российский кардиологический журнал. 2015; 9 (125): 96–102.Drapkina O.M., Deeva T.A. Galectin-3 – biomarker of fibrosis in patients with metabolic syndrome. Russ J Cardiol. 2015; 9 (125): 96–102.Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 Dec 3; 21 (23): 9232.Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 Dec 3; 21 (23): 9232.Shevchenko O, Tsirulnikova O, Sharapchenko S, Pashkov I, Bekov M, Shigaev E et al. MiR-339 and galectin-3: diagnostic value in patients with airway obstruction after lung transplantation. Transpl Int. 2021 Sep; 34 (9): 1733–1739. doi: 10.1111/tri.13986.Shevchenko O, Tsirulnikova O, Sharapchenko S, Pashkov I, Bekov M, Shigaev E et al. MiR-339 and galectin-3: diagnostic value in patients with airway obstruction after lung transplantation. Transpl Int. 2021 Sep; 34 (9): 1733–1739. doi: 10.1111/tri.13986.An Y, Xu S, Liu Y, Xu X, Philips CA, Chen J et al. Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021 Oct 27; 8: 744518.An Y, Xu S, Liu Y, Xu X, Philips CA, Chen J et al. Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021 Oct 27; 8: 744518.Sotomayor CG, Te Velde­Keyzer CA, Diepstra A, van Londen M, Pol RA, Post A et al. Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study. Transplantation. 2021 May 1; 105 (5): 1106–1115.Sotomayor CG, Te Velde­Keyzer CA, Diepstra A, van Londen M, Pol RA, Post A et al. Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study. Transplantation. 2021 May 1; 105 (5): 1106–1115.Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T et al. Regulation of transforminggrowth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012; 185: 537–546.Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T et al. Regulation of transforminggrowth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012; 185: 537–546.Calvier L, Martinez­Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015; 3: 59–67.Calvier L, Martinez­Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015; 3: 59–67.Tsai MT, Yang RB, Ou SM, Tseng WC, Lee KH, Yang CY et al. Plasma Galectin-9 Is a Useful Biomarker for Predicting Renal Function in Patients Undergoing Native Kidney Biopsy. Arch Pathol Lab Med. 2023 Feb 1; 147 (2): 167–176.Tsai MT, Yang RB, Ou SM, Tseng WC, Lee KH, Yang CY et al. Plasma Galectin-9 Is a Useful Biomarker for Predicting Renal Function in Patients Undergoing Native Kidney Biopsy. Arch Pathol Lab Med. 2023 Feb 1; 147 (2): 167–176.O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013; 24: 1470–1477.O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013; 24: 1470–1477.Boutin L, Dépret F, Gayat E, Legrand M, Chadjichristos CE. Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target. Int J Mol Sci. 2022 Mar 14; 23 (6): 3124.Boutin L, Dépret F, Gayat E, Legrand M, Chadjichristos CE. Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target. Int J Mol Sci. 2022 Mar 14; 23 (6): 3124.Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander. Am J Nephrol. 2016; 43 (5): 305–317.Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander. Am J Nephrol. 2016; 43 (5): 305–317.Prud’homme M, Coutrot M, Michel T, Boutin L, Genest M, Poirier F et al. Acute kidney injury induces remote cardiac damage and dysfunction through the Galectin-3 pathway. JACC Basic Transl Sci. 2019; 4 (6): 717–732.Prud’homme M, Coutrot M, Michel T, Boutin L, Genest M, Poirier F et al. Acute kidney injury induces remote cardiac damage and dysfunction through the Galectin-3 pathway. JACC Basic Transl Sci. 2019; 4 (6): 717–732.Sun H, Jiang H, Eliaz A, Kellum JA, Peng Z, Eliaz I. Galectin-3 in septic acute kidney injury: a translational study. Crit Care. 2021; 25 (1): 109.Sun H, Jiang H, Eliaz A, Kellum JA, Peng Z, Eliaz I. Galectin-3 in septic acute kidney injury: a translational study. Crit Care. 2021; 25 (1): 109.Ou SM, Tsai MT, Chen HY, Li FA, Lee KH, Tseng WC et al. Urinary Galectin-3 as a Novel Biomarker for the Prediction of Renal Fibrosis and Kidney Disease Progression. Biomedicines. 2022 Mar 2; 10 (3): 585.Ou SM, Tsai MT, Chen HY, Li FA, Lee KH, Tseng WC et al. Urinary Galectin-3 as a Novel Biomarker for the Prediction of Renal Fibrosis and Kidney Disease Progression. Biomedicines. 2022 Mar 2; 10 (3): 585.Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular Atrophy and Interstitial Fibrosis after Renal Transplantation Is Dependent on Galectin-3. Transplantation. 2012; 93: 477–484.Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular Atrophy and Interstitial Fibrosis after Renal Transplantation Is Dependent on Galectin-3. Transplantation. 2012; 93: 477–484.Karatolios K, Chatzis G, Holzendorf V, Störk S, Richter A, Binas D et al. Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy. Dis Markers. 2018 Jun 19; 2018: 2958219.Karatolios K, Chatzis G, Holzendorf V, Störk S, Richter A, Binas D et al. Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy. Dis Markers. 2018 Jun 19; 2018: 2958219.Binas D, Daniel H, Richter A, Ruppert V, Schlüter KD, Schieffer B, Pankuweit S. The prognostic value of sST2 and galectin-3 considering different aetiologies in nonischaemic heart failure. Open Heart. 2018 Feb 26; 5 (1): e000750. doi: 10.1136/openhrt-2017-000750.Binas D, Daniel H, Richter A, Ruppert V, Schlüter KD, Schieffer B, Pankuweit S. The prognostic value of sST2 and galectin-3 considering different aetiologies in nonischaemic heart failure. Open Heart. 2018 Feb 26; 5 (1): e000750. doi: 10.1136/openhrt-2017-000750.Щукин ЮВ, Березин ИИ, Медведева ЕА, Селезнев ЕИ, Дьячков ВА, Слатова ЛН. О значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных с хронической сердечной недостаточностью. Российский кардиологический журнал. 2013; 2 (100): 45–49.Shchukin YuB, Berezin II, Medvedeva EA, Seleznev EI, Dyachkov VA, Slatova LN. Galectin-3 as a marker and mediator of endogenous inflammation and nitrosylation oxidative stress in patients with chronic heart failure. Russ J Cardiol 2013; 2 (100): 45–49.Беленков ЮН, Татенкулова СН, Мареев ВЮ, Масенко ВП, Балахонова ТВ, Трипотень МИ и др. Взаимосвязь уровня провоспалительных факторов с выраженностью сердечной недостаточности при ишемической болезни сердца. Сердечная недостаточность 2009; 10 (3): 137–139.Belenkov YuN, Tatenkulova SN, Mareev VYu, Masenko VP, Balakhonova TV, Tripoten’ MI i dr. Vzaimosvjaz’ urovnja provospalitel’nyh faktorov s vyrazhennost’ju serdechnoj nedostatochnosti pri ishemicheskoj bolezni serdca. Serdechnaja nedostatochnost’. 2009; 10 (3): 137–139.Шевченко АО, Никитина ЕА, Колоскова НН, Шевченко ОП, Готье СВ. Контролируемая артериальная гипертензия и выживаемость без нежелательных событий у реципиентов сердца. Кардиоваскулярная терапия и профилактика. 2018; 17 (4): 4–11.Shevchenko AО, Nikitina EA, Koloskova NN, Shevchenko ОP, Gautier SV. Controlled arterial hypertension and adverse event free survival rate in heart recipients. Cardiovascular Therapy and Prevention. 2018; 17 (4): 4–11.Hughes A, Okasha O, Farzaneh­Far A, Kazmirczak F, Nijjar PS, Velangi P et al. Myocardial Fibrosis and Prognosis in Heart Transplant Recipients. Circ Cardiovasc Imaging. 2019 Oct; 12 (10): e009060. doi: 10.1161/CIRCIMAGING.119.009060.Hughes A, Okasha O, Farzaneh­Far A, Kazmirczak F, Nijjar PS, Velangi P et al. Myocardial Fibrosis and Prognosis in Heart Transplant Recipients. Circ Cardiovasc Imaging. 2019 Oct; 12 (10): e009060. doi: 10.1161/CIRCIMAGING.119.009060.Шевченко ОП, Улыбышева АА, Гичкун ОЕ, Можейко НП, Стаханова ЕА, Кван ВС, Шевченко АО. Галектин-3 при отторжении и фиброзе трансплантированного сердца. Вестник трансплантологии и искусственных органов. 2019; 21 (3): 62–68.Shevchenko OP, Ulybysheva AA, Gichkun OE, Mozheiko NP, Stakhanova EA, Kvan VS, Shevchenko AO. Galectin-3 in heart transplant rejection and fibrosis. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (3): 62–68.Шевченко ОП, Улыбышева АА, Можейко НП, Гичкун ОЕ, Стаханова ЕА, Васильева ВП, Шевченко АО. Диагностическая значимость галектина-3 при патологии миокарда трансплантированного сердца. Вест ник трансплантологии и искусственных органов. 2020; 8–15.Shevchenko OP, Ulybysheva AA, Mozheiko NP, Gichkun OE, Stakhanova EA, Vasilieva VP, Shevchenko AO. Diagnostic value of galectin-3 in heart transplant recipients with myocardial complications. Russian Journal of Transplantology and Artificial Organs. 2020; 22 (1): 8–15.Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017 Feb; 19 (2): 177–191. doi: 10.1002/ejhf.696.Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017 Feb; 19 (2): 177–191. doi: 10.1002/ejhf.696.Kyselovic J, Leddy JJ. Cardiac Fibrosis: The Beneficial Effects of Exercise in Cardiac Fibrosis. Exercise for Cardiovascular Disease Prevention and Treatment: From Molecular to Clinical. Part 1. 2017: 257–268.Kyselovic J, Leddy JJ. Cardiac Fibrosis: The Beneficial Effects of Exercise in Cardiac Fibrosis. Exercise for Cardiovascular Disease Prevention and Treatment: From Molecular to Clinical. Part 1. 2017: 257–268.Cervantes­Alvarez E, Limon­de la Rosa N, Vilatoba M, Pérez­Monter C, Hurtado­Gomez S, Martinez­Cabrera C et al. Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications. Liver Int. 2022 Oct; 42 (10): 2260–2273.Cervantes­Alvarez E, Limon­de la Rosa N, Vilatoba M, Pérez­Monter C, Hurtado­Gomez S, Martinez­Cabrera C et al. Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications. Liver Int. 2022 Oct; 42 (10): 2260–2273.Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011; 6 (6): e21381.Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011; 6 (6): e21381.Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung. 2015 Oct; 193 (5): 677–681.Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung. 2015 Oct; 193 (5): 677–681.Bennett D, Lanzarone N, Fossi A, Perillo F, De Vita E, Luzzi L et al. Pirfenidone in chronic lung allograft dysfunction: a single cohort study. Panminerva Med. 2020; 62 (3): 143–149.Bennett D, Lanzarone N, Fossi A, Perillo F, De Vita E, Luzzi L et al. Pirfenidone in chronic lung allograft dysfunction: a single cohort study. Panminerva Med. 2020; 62 (3): 143–149.Cameli P, Bargagli E, Fossi A, Bennett D, Voltolini L, Refini RM et al. Exhaled nitric oxide and carbon monoxide in lung transplanted patients. Respir Med. 2015; 109 (9): 1224–1229.Cameli P, Bargagli E, Fossi A, Bennett D, Voltolini L, Refini RM et al. Exhaled nitric oxide and carbon monoxide in lung transplanted patients. Respir Med. 2015; 109 (9): 1224–1229.Bergantini L, d’Alessandro M, De Vita E, Perillo F, Fossi A, Luzzi L et al. Regulatory and effector cell disequilibrium in patients with acute cellular rejection and chronic lung allograft dysfunction after lung transplantation: comparison of peripheral and alveolar distribution. Cells. 2021; 10 (4): 780.Bergantini L, d’Alessandro M, De Vita E, Perillo F, Fossi A, Luzzi L et al. Regulatory and effector cell disequilibrium in patients with acute cellular rejection and chronic lung allograft dysfunction after lung transplantation: comparison of peripheral and alveolar distribution. Cells. 2021; 10 (4): 780.DerHovanessian A, Wallace WD, Lynch JP 3rd, Belperio JA, Weigt SS. Chronic lung allograft dysfunction: evolving concepts and therapies. Semin Respir Crit Care Med. 2018; 39 (2): 155–171.DerHovanessian A, Wallace WD, Lynch JP 3rd, Belperio JA, Weigt SS. Chronic lung allograft dysfunction: evolving concepts and therapies. Semin Respir Crit Care Med. 2018; 39 (2): 155–171.d’Alessandro M, Bergantini L, Fossi A, De Vita E, Perillo F, Luzzi L et al. The Role of Galectins in Chronic Lung Allograft Dysfunction. Lung. 2021 Jun; 199 (3): 281–288. doi: 10.1007/s00408-021-00449-3.d’Alessandro M, Bergantini L, Fossi A, De Vita E, Perillo F, Luzzi L et al. The Role of Galectins in Chronic Lung Allograft Dysfunction. Lung. 2021 Jun; 199 (3): 281–288. doi: 10.1007/s00408-021-00449-3.A Phase 2a Study of Weekly Doses of GCS-100 in Patients with Chronic Kidney Disease, 9 January 2022.A Phase 2a Study of Weekly Doses of GCS-100 in Patients with Chronic Kidney Disease, 9 January 2022.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov; 102 (5S): S1–S127. doi: 10.1016.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov; 102 (5S): S1–S127. doi: 10.1016.Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B et al. Galectin-3 Inhibition with Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021 Jan 6; 6 (1): 12–21.Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B et al. Galectin-3 Inhibition with Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021 Jan 6; 6 (1): 12–21.Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A et al. Target-Inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis. Eur Respir J. 2021 May 27; 57 (5): 2002559. doi: 10.1183/13993003.02559-2020.Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A et al. Target-Inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis. Eur Respir J. 2021 May 27; 57 (5): 2002559. doi: 10.1183/13993003.02559-2020.

The authors declare that there are no conflicts of interest present.